Key takeaways (for owners)

• Multiples are earned, not assumed: two hospices with the same EBITDA can sell at very different multiples based on compliance and earnings quality.
• EBITDA is the common language: most buyers price hospices using an EBITDA multiple, validated by an income approach (DCF) and “quality of earnings.”
• Compliance is a value driver: documentation integrity, audit history, cap management, and survey outcomes often move the multiple more than owners expect.
• Preparation creates leverage: clean books, normalized EBITDA, diversified referrals, and operational depth reduce buyer “risk discounts.”

1) Current market environment and what “hospice multiples” really mean

In hospice M&A, “multiples” almost always refers to an EBITDA multiple…the price paid divided by a
hospice’s normalized EBITDA. In plain terms: if a hospice produces $1,000,000 in normalized EBITDA and sells for $7,000,000,
that’s a 7.0× EBITDA multiple.

In the last several years, hospice valuations have been shaped by (1) capital costs and interest rates, (2) buyer competition for
scarce quality assets, and (3) increased regulatory scrutiny…especially around eligibility documentation, survey outcomes, and cap risk.
Owners should assume buyers will be more disciplined than the 2021–2022 peak era, but still willing to pay for lower-risk platforms.

Practical reality: the “multiple” is a price for risk. Stable cash flow + defensible referrals + strong compliance + operational depth
= higher multiple. The reverse = risk discounts, holdbacks, escrow, or earnouts.

A simple valuation benchmark table (how buyers often segment risk)

Note: Actual multiples vary by market conditions, buyer profile, and agency specifics. This table is an educational framework to explain how buyers commonly segment risk and where the multiple “moves.”

2) The drivers that move hospice EBITDA multiples

Earnings quality: “real EBITDA” vs “paper EBITDA”

Buyers don’t pay a multiple on your bookkeeping—they pay a multiple on normalized, defensible earnings. That means adjusting EBITDA for
non-recurring items, owner compensation above market, discretionary expenses, and any unusual items that won’t recur post-close. If your financial statements are cash-basis or inconsistent, buyers often price in extra risk (and extra diligence cost).

Referral durability and concentration

Multiples compress when revenue depends on one facility, one hospital system, or one “rainmaker.” Buyers prefer a diversified pipeline, documented referral relationships, and a repeatable outreach system that survives ownership change.

Census stability, LOS distribution, and discharge profile

Buyers analyze admissions, average daily census, length-of-stay distributions, live discharges, and diagnosis mix to understand both sustainability and compliance risk. A clean clinical story supports the multiple; anomalies invite deeper scrutiny.

Operating infrastructure and “key person risk”

If your hospice depends on the owner for admissions, compliance, and staffing, buyers will usually discount the multiple or require an earnout. A capable leadership bench, documented processes, and stable staffing reduce perceived risk.

3) Asset-based vs income-based vs market approach (and when each matters)

Market approach (multiples from comparable transactions)

The market approach applies a multiple (often EBITDA) derived from comparable hospice transactions and public-market comps.
It’s widely used because it mirrors how deals are actually priced. The limitation: “comparable” does not mean “identical.”
Skilled valuation work adjusts for size, growth, quality, and risk.

Income approach (DCF and cash-flow-based valuation)

The income approach values your hospice based on forecasted future cash flows discounted to present value.
It’s useful for explaining why a multiple should be higher (e.g., strong growth runway) or why a multiple should be lower (e.g., margin pressure).
The weakness is assumption sensitivity; small changes in growth or discount rate can materially change the valuation.

Asset-based approach (rarely primary for profitable hospices)

Asset-based valuation focuses on net asset value and is typically not the primary method for a profitable hospice because the most valuable “assets”
are intangible (brand, clinical operations, referral relationships, and cash flow). It becomes more relevant for distressed scenarios or when earnings are inconsistent.

4) How regulatory compliance impacts hospice valuation

If you want to understand why two hospices with similar EBITDA sell at dramatically different prices,
start with compliance. Hospice is heavily Medicare-reimbursed, and buyers are acutely aware of documentation integrity,
eligibility risk, survey outcomes, billing audits, and hospice cap exposure.

What buyers commonly review

• Survey history: state survey findings, plans of correction, repeat deficiencies
• Eligibility documentation: physician certifications, face-to-face encounters, LCD alignment, clinical narrative strength
• Billing integrity: ADRs, ZPIC/UPIC activity, RAC reviews (if applicable), denial trends
• Hospice cap management: historical cap status, rolling cap exposure, reserve practices
• Policies and training: compliance program, audit cadence, corrective action documentation

If you want a public starting point for quality metrics and how CMS frames hospice reporting,
review CMS’s Hospice Care Compare / Care Compare resources:
https://www.medicare.gov/care-compare/
and the CMS Hospice Quality Reporting Program overview:
https://www.cms.gov/medicare/quality/hospice/hospice-quality-reporting-program.

5) How much does a professional hospice valuation typically cost?

The cost of a professional valuation depends on purpose (sale planning vs. IRS vs. litigation), complexity, and the
quality of your financial records. As an educational benchmark, many small-to-mid healthcare business valuations often land in the
low four-figures to low five-figures, with more complex or formal opinions costing more.

What affects the fee most

• Scope: calculation vs. full narrative valuation report, and whether a Quality of Earnings is required
• Complexity: multi-entity structures, related-party transactions, multiple locations
• Data readiness: accrual financials, reconciled AR/AP, consistent payroll and census reporting
• Timeline: rush engagements usually increase cost

6) Buyer steps and pitfalls in a hospice acquisition

Buyers who win in hospice acquisitions follow a disciplined sequence: regulatory feasibility → diligence → structure → transition.
The biggest pitfalls are almost always compliance-related, licensing/CHOW timing-related, or earnings-quality-related.

Essential steps

1. Regulatory feasibility: licensure transfer rules, CHOW timelines, any state-level constraints
2. Financial diligence: QofE, EBITDA normalization, AR aging, working capital needs
3. Clinical/compliance diligence: chart sampling, eligibility integrity, survey and audit history
4. Deal structure: asset vs stock, indemnities, escrow for identified liabilities
5. Transition plan: staff retention, referral continuity, operational handoff

Common pitfalls to avoid

• Underestimating cap exposure or assuming historical cap refunds “won’t matter”
• Failing to stress test referral concentration under ownership change
• Overpaying on “peak multiple” anecdotes without validating earnings quality
• Not planning licensing/CHOW timing and operational continuity

7) How hospice owners prepare to maximize sale price

Owner prep checklist

• Financial readiness: accrual statements, consistent reporting, documented add-backs, AR cleanup
• Compliance readiness: internal audits, documentation training, survey packet, cap tracking
• Referral durability: reduce concentration risk; document pipeline and outreach system
• Operational depth: leadership bench, SOPs, cross-training, staffing stability
• Data room readiness: fast, organized diligence reduces risk discounts and accelerates timelines

If you’re building a broader exit plan, these pages can help owners frame the process:
The 7 steps to selling and our Seller FAQs.

Downloadable guide

Hospice Sale Readiness Checklist (PDF): a step-by-step checklist owners can use 6–18 months before market.
Include: financial cleanup, QofE readiness, compliance packet, referral concentration audit, cap tracking, data room index, transition planning.

Request the checklist

Join our buyer network